Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

CD22 as a target for cancer therapy.

Tu X, LaVallee T, Lechleider R.

J Exp Ther Oncol. 2011;9(3):241-8. Review.

PMID:
22070056
2.

Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.

Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3304s-3314s.

PMID:
10541379
3.

Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.

Leonard JP, Goldenberg DM.

Oncogene. 2007 May 28;26(25):3704-13. Review.

PMID:
17530024
4.

Monoclonal antibody-based therapeutics for leukemia.

Li Y, Zhu Z.

Expert Opin Biol Ther. 2007 Mar;7(3):319-30. Review.

PMID:
17309324
5.

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.

Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S.

6.

CD22 as a target of passive immunotherapy.

Cesano A, Gayko U.

Semin Oncol. 2003 Apr;30(2):253-7. Review.

PMID:
12720147
7.

Epratuzumab: targeting B-cell malignancies through CD22.

Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Ashe M, Fiore JM, Leonard JP.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3991S-4S. Review.

8.

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Fanale MA, Younes A.

Drugs. 2007;67(3):333-50. Review.

PMID:
17335294
9.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK.

Blood. 2004 Mar 1;103(5):1807-14. Epub 2003 Nov 13.

10.

Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.

Robak T.

Curr Cancer Drug Targets. 2008 Mar;8(2):156-71. Review.

PMID:
18336199
11.

CD22-directed monoclonal antibody therapy for lymphoma.

Siegel AB, Goldenberg DM, Cesano A, Coleman M, Leonard JP.

Semin Oncol. 2003 Aug;30(4):457-64. Review.

PMID:
12939714
12.

Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.

Dennie TW, Kolesar JM.

Clin Ther. 2009;31 Pt 2:2290-311. doi: 10.1016/j.clinthera.2009.11.031. Review.

PMID:
20110042
13.

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.

DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann P, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK.

Cancer Immunol Immunother. 2005 Jan;54(1):11-24.

PMID:
15693135
14.

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, Kreitman RJ, Peschel C, Pastan I, Meyer Zum Büschenfelde C, Ringshausen I.

Haematologica. 2012 May;97(5):771-9. doi: 10.3324/haematol.2011.049155. Epub 2011 Dec 16.

15.

Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.

DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR, Damle NK.

Clin Cancer Res. 2004 Dec 15;10(24):8620-9.

16.
17.

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK.

Semin Oncol. 1999 Oct;26(5 Suppl 14):66-73. Review.

PMID:
10561020
18.

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM.

Clin Cancer Res. 2004 Aug 15;10(16):5327-34.

19.

First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.

Hainsworth JD.

Semin Oncol. 2003 Feb;30(1 Suppl 2):9-15. Review.

PMID:
12652459
20.

Supplemental Content

Support Center